Loss of the tumor suppressor PTEN is a frequent event in prostate cancer that contributes to tumor growth and therapeutic resistance through oncogenic PI3K--AKT--mTOR signaling, increased~genomic instability, impaired DNA damage repair, pro-tumorigenic reprograming of the tumor microenvironment and immunosuppression. This evidence concerns the gene PTEN and prostate carcinoma.